BUZZ-PepGen falls after US FDA puts partial hold on mid‑stage drug trial
Reuters03-05
BUZZ-PepGen falls after US FDA puts partial hold on mid‑stage drug trial
** Shares of drug developer PepGen PEPG.O fall 17% to $5.60 in extended trading
** PEPG says the U.S. FDA has put a partial clinical hold on its mid‑stage trial of a rare muscle disease drug
** The drug, PGN‑EDODM1, is being tested for myotonic dystrophy type 1, which causes progressive muscle weakness
** Co says the health regulator's concerns relate to earlier lab and animal studies the company submitted
** PEPG says it's working with the FDA to address the questions and will submit additional info
** PEPG rose 72.7% in 2025
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments